

A provider's guide to helping patients afford Benzphetamine. Covers discount cards, generics, cost conversations, and savings strategies.
For providers prescribing Benzphetamine (Didrex, Regimex), the clinical decision is only half the equation. If patients can't afford the medication, they won't take it — or they'll ration doses, skip refills, or abandon treatment entirely.
Weight loss pharmacotherapy already faces significant coverage barriers. Many commercial insurers exclude anti-obesity medications from their formularies. Medicare Part D generally does not cover weight loss drugs. And patients who lack prescription drug coverage face the full cash price, which can range from $70 to over $600 depending on the pharmacy and whether discount programs are applied.
As a prescriber, you're uniquely positioned to help patients navigate these financial obstacles. This guide outlines the practical tools and strategies available in 2026.
Understanding the pricing landscape helps you set patient expectations and guide them toward the most affordable options:
The spread between the lowest discount price and the full cash price is substantial — often 5x to 8x — which means the choice of pharmacy and discount program significantly impacts out-of-pocket cost.
Coverage for Benzphetamine is inconsistent across payers:
When coverage is denied, the strategies below become essential for maintaining patient access.
Unlike many brand-name medications, there is no manufacturer savings program currently available for Benzphetamine. Neither the brand-name products (Didrex, Regimex) nor generic manufacturers offer copay cards, patient assistance programs, or direct-to-patient savings initiatives.
This means patients and providers must rely on third-party discount programs and other strategies outlined below.
Third-party prescription discount platforms are the primary cost-reduction tool for Benzphetamine. These programs negotiate rates with pharmacies and pass savings to the consumer at no cost.
Consider these practice-level strategies:
Benzphetamine is available as a generic, and generic substitution should always be the default recommendation. The cost difference is significant:
Ensure prescriptions are written to allow generic substitution (avoid "Dispense as Written" unless clinically necessary). Verify with patients that the pharmacy is dispensing the generic formulation.
While no manufacturer-sponsored patient assistance program exists for Benzphetamine, patients in financial hardship may benefit from broader assistance resources:
These resources are particularly valuable for patients who are uninsured, on fixed incomes, or facing financial hardship.
Benzphetamine pricing varies significantly between pharmacies — even within the same zip code. Encourage patients to:
Price transparency tools empower patients to make informed decisions. The difference between the most and least expensive pharmacy options can easily exceed $400 for the same 90-tablet supply.
Many patients are reluctant to bring up cost concerns. Proactively addressing affordability normalizes the conversation and improves adherence:
For patients who find Benzphetamine unaffordable despite discount programs, consider therapeutic alternatives. Phentermine (Adipex-P, Lomaira) is often less expensive and more widely covered by insurance. Orlistat (Alli) is available over the counter without a prescription. For a comprehensive comparison, refer to our guide on alternatives to Benzphetamine.
Cost isn't the only barrier — availability can also be challenging. As a Schedule III controlled substance subject to DEA production quotas, Benzphetamine supply can be affected by broader stimulant shortages. For strategies on helping patients locate pharmacies with stock, see our provider's guide to finding Benzphetamine in stock.
The absence of a manufacturer savings program makes Benzphetamine a medication where provider-initiated cost guidance is especially important. By recommending generic substitution, directing patients to discount card platforms, proactively discussing cost, and monitoring for affordability barriers at follow-up, you can significantly improve treatment adherence and patient outcomes.
The tools are available — the key is integrating them into your prescribing workflow. For more provider-focused resources, visit MedFinder for Providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.